AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Summit Therapeutics Inc. Director's Dealing 2022

Jun 2, 2022

30436_dirs_2022-06-02_1f5fbfd4-d4eb-451b-9bf5-006d82efe61c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2022-05-31

Reporting Person: Dhingra Ankur (Chief Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	26500	Direct
Common Stock	13538	Indirect

Footnotes

F1: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.